| Revenue growth | FY26 revenue ₹67,137 million; Q4 showed sequential growth. |
|---|---|
| Margins | Gross margin at 58%; EBITDA margin resilient at 25%. |
| Order book | CSM order book remains steady at $1.1-1.2 billion. |
| Demand visibility | Expect recovery in H2 FY27; domestic momentum tied to Kharif. |
| Management confidence | High confidence in NCE transition and Pharma CRDMO scale-up. |
Growth
FY26 revenue at ₹67,137M; Pharma segment grew 40% YoY. Q4 revenue reached ₹15,652M with sequential growth.
Outlook
Guidance for positive FY27 growth led by NCE launch and Pharma scale-up. FY27 capex planned at ₹700-800cr.
Risks
Global AgChem downcycle, uneven recovery, Middle East conflict disruptions, and high channel inventory in domestic markets.
Earnings Call filed with NSE, NSE: PIIND. Summary written with AI assistance from the document.
PI Industries Ltd: key numbers
- Share price
- ₹2,250.00
- Market cap
- ₹34,137 Cr
- Revenue (annual)
- ₹6,714 Cr
- Net profit (annual)
- ₹1,321 Cr
- P/E (TTM)
- 29.3×Sector 37.2×
- Promoter holding
- 46.09%+0.00% QoQ
- FII holding
- 14.83%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from PI Industries Ltd
All →PI Industries Other Announcement
Bhavina J Dholariya, an immediate relative of an insider, sold equity shares of PI Industries Ltd. The market sale was valued at ₹0.12 Crore.
- Value
- ₹0.12 Cr
PI Industries Product Launch
PI Industries received registration for its indigenously developed insecticide, 'Pioxaniliprole' (branded 'Pioxazon'), marking a key milestone in its agricultural innovation journey.
PI Industries Other Announcement
Designated person Jayesh Dholariya disclosed the sale of 3,000 equity shares via gift, totaling approximately Rs. 0.75 Crore.
- Value
- ₹0.75 Cr
PI Industries Annual General Meeting
PI Industries held its 79th Annual General Meeting on August 14, 2026. Shareholders approved all nine agenda items, including financial statements and dividend payments.
PI Industries Earnings Call Transcript: Key Takeaways
PI Industries Q1 FY27 results show resilience amidst global agrochemical headwinds, maintaining healthy EBITDA margins at 22% despite revenue softness. Management remains optimistic about a second-half recovery driven by domestic monsoon improvement and new product scale-ups.
- Call
- Guides 5% growth
PI Industries Investor Presentation: Key Takeaways
PI Industries Q1 FY27 consolidated revenue fell 10% to ₹17,023 Mn, with EBITDA down 29% and PAT down 39% due to global agrochemical headwinds and cyclical disruptions.